Ashwin Gollerki

  • Citations Per Year
Learn More
RATIONALE BMS-188797 is one of several novel taxanes in ongoing clinical development. It has superior activity in experimental tumor models when compared with paclitaxel. BMS-188797 has a single C-4 modification, a 4-desacetyl-4-methylcarbonate, compared with paclitaxel. METHODS We did a phase I study, in which a fixed dose of carboplatin was combined(More)
  • 1